Many patients with schizophrenia experience residual symptoms despite currently available treatments that affect quality of life and overall function. Treatment with a variety of different agents—as adjuncts to antipsychotics—has either failed to show consistent, robust effects on psychopathology, or needs replication in larger studies.
By contrast, several pharmacologic strategies, including adjunctive topiramate, have been successful in reducing antipsychotic-induced weight gain.
Topiramate is approved by the US FDA as an anti-epileptic and anti-migraine treatment. In patients with epilepsy and obesity and/or type 2 diabetes mellitus, topiramate has been associated with weight loss and improved glucose homeostasis, potentially through appetite reduction.
Adjunctive topiramate was also associated with significantly greater reduction in PANSS positive, negative, and general subscale scores.
Furthermore, topiramate was associated with significantly lower body weight (SMD = -0.71) and BMI (SMD = -1.04), with medium-to-large and large effect sizes, respectively. One trial also found significant advantages for adjunctive topiramate regarding effects on insulin, glucose, and total and low-density lipoprotein cholesterol.
Adjunctive Topiramate sounds fascinating. Interested in losing weight .Are there any negative side effects? Can one order this online or do you need a doctor’s prescription?
tried this med numerous times and couldn’t get past 50mg. it does have a calming effect but i couldn’t remember the most basic things on it. Hence the name “Dopamax”